OBJECTIVE: To report the prevalence of ocular complications of AIDS in the era of highly active antiretroviral therapy (HAART). DESIGN: Cohort study. PARTICIPANTS: Patients with AIDS, 13 years or older. METHODS: History, eye examination, and laboratory testing at enrollment. MAIN OUTCOME MEASURE: Frequency of ocular complications at enrollment. RESULTS: As of March 31, 2003, 1632 participants with AIDS were enrolled. The cohort had a history of severe immune deficiency, as evidenced by a median nadir CD4+ T-cell count of 30 cells per microliter. At enrollment, the median CD4+ T-cell count was 164 cells per microliter. CD4+ T-cell counts were <50 in 24.1% but > or =100 in 63.6% and > or =200 in 43.0%. Cytomegalovirus (CMV) retinitis was present in 22.1%, whereas other ocular opportunistic infections each were present in < or =0.6%. The incidence of CMV retinitis estimated from retrospective data was 5.60/100 person-years. Of the 360 patients with CMV retinitis, 22.5% were newly diagnosed at enrollment, and the remainder had more long-standing CMV retinitis (median, 2.8 years). CONCLUSIONS: Although there is the possibility of oversampling patients with AIDS and ocular complications (as compared with a random sample), which would lead to increased estimates of prevalent and incident ocular morbidities, these data still suggest a substantial decline in the incidence of CMV retinitis from the pre-HAART era. Nevertheless, new cases of CMV retinitis continue to occur, and there is a population of patients with long-standing retinitis who will require management.
OBJECTIVE: To report the prevalence of ocular complications of AIDS in the era of highly active antiretroviral therapy (HAART). DESIGN: Cohort study. PARTICIPANTS: Patients with AIDS, 13 years or older. METHODS: History, eye examination, and laboratory testing at enrollment. MAIN OUTCOME MEASURE: Frequency of ocular complications at enrollment. RESULTS: As of March 31, 2003, 1632 participants with AIDS were enrolled. The cohort had a history of severe immune deficiency, as evidenced by a median nadir CD4+ T-cell count of 30 cells per microliter. At enrollment, the median CD4+ T-cell count was 164 cells per microliter. CD4+ T-cell counts were <50 in 24.1% but > or =100 in 63.6% and > or =200 in 43.0%. Cytomegalovirus (CMV) retinitis was present in 22.1%, whereas other ocular opportunistic infections each were present in < or =0.6%. The incidence of CMV retinitis estimated from retrospective data was 5.60/100 person-years. Of the 360 patients with CMV retinitis, 22.5% were newly diagnosed at enrollment, and the remainder had more long-standing CMV retinitis (median, 2.8 years). CONCLUSIONS: Although there is the possibility of oversampling patients with AIDS and ocular complications (as compared with a random sample), which would lead to increased estimates of prevalent and incident ocular morbidities, these data still suggest a substantial decline in the incidence of CMV retinitis from the pre-HAART era. Nevertheless, new cases of CMV retinitis continue to occur, and there is a population of patients with long-standing retinitis who will require management.
Authors: Efe Sezgin; Sher L Hendrickson; Douglas A Jabs; Mark L Van Natta; Richard A Lewis; Jennifer L Troyer; Stephen J O'Brien Journal: J Acquir Immune Defic Syndr Date: 2010-08 Impact factor: 3.731
Authors: Partho S Kalyani; Gary N Holland; Amani A Fawzi; Tiago E F Arantes; Fei Yu; Alfredo A Sadun Journal: Am J Ophthalmol Date: 2012-01-15 Impact factor: 5.258
Authors: Elizabeth A Sugar; Douglas A Jabs; Alka Ahuja; Jennifer E Thorne; Ronald P Danis; Curtis L Meinert Journal: Am J Ophthalmol Date: 2012-02-04 Impact factor: 5.258
Authors: Douglas A Jabs; Alka Ahuja; Mark Van Natta; Alice Lyon; Sunil Srivastava; Sapna Gangaputra Journal: Ophthalmology Date: 2010-07-29 Impact factor: 12.079
Authors: Sapna Gangaputra; Lea Drye; Vijay Vaidya; Jennifer E Thorne; Douglas A Jabs; Alice T Lyon Journal: Am J Ophthalmol Date: 2012-10-12 Impact factor: 5.258
Authors: Stacy L Pineles; Joseph L Demer; Gary N Holland; Susan S Ransome; Laura Bonelli; Federico G Velez Journal: J AAPOS Date: 2012-11-14 Impact factor: 1.220